PubRank

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Clinical Trial ID NCT01866319

PubWeight™ 40.30‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01866319

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015 8.64
2 Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013 4.78
3 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
4 Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015 1.67
5 Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol 2015 1.60
6 Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer 2018 1.38
7 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
8 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
9 Immune modulation for cancer therapy. Br J Cancer 2014 1.15
10 Antibodies to watch in 2014. MAbs 2013 1.14
11 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
12 New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 2015 1.12
13 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
14 Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015 1.04
15 Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer 2016 1.00
16 Pembrolizumab. J Immunother Cancer 2015 0.99
17 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
18 Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014 0.98
19 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
20 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol 2015 0.97
21 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
22 Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther 2015 0.88
23 Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J 2014 0.88
24 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
25 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
26 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
27 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
28 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
29 Pembrolizumab for the treatment of advanced melanoma. Expert Opin Orphan Drugs 2016 0.80
30 PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. PLoS One 2016 0.78
31 Melanoma immunotherapy. Cancer Biol Ther 2014 0.76
32 Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother 2016 0.75
Next 100